inhibitors

New Drug Report 2020 -10

New Drug Report 2020 -10

The Janus kinase (JAK1) inhibitor Figotinib (Jyseleca; Gilead) was approved in Japan and the European Union in September 2020. The approved indication in Japan is the treatment of patients with […]

New Drug Report 2020 -9

New Drug Report 2020 -9

13 Anti-tumor drugs Trastuzumab deruxtecan (Enhertu), an antibody drug conjugate (ADC) developed by Japan’s Daiichi Sankyo and authorized by AstraZeneca for co-development and commercialization, was approved by the FDA at […]

New Drug Report 2020 -7

New Drug Report 2020 -7

11 Anti-infective drugs The 2020 COVID-19 pandemic will linger in everyone’s memory forever. In this year, Remdesivir (Veklury; Gilead), as the first anti-viral treatment of the disease, obtained rapid development […]

Nat Commun: SKP2 inhibitors such as niclosamide reduce MERS-CoV coronavirus replication in vitro by up to 28,000 times

Nat Commun: SKP2 inhibitors such as niclosamide reduce MERS-CoV coronavirus replication in vitro by up to 28,000 times

The Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) was first discovered in 2012 and can cause severe or even fatal pneumonia. There is currently no effective treatment for MERS-CoV. In […]